Every S-1 that SRX GLOBAL INC (SRXH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow SRXH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SRXH filings page.
SRx Health Solutions, Inc. is registering up to 187,544,974 shares of common stock for resale by existing selling stockholders. These shares come primarily from recent financings, including July and October PIPE transactions, an April 2025 private placement, shares issued to service providers, exchangeable shares tied to SRx Health Solutions (Canada), Inc., and a share exchange with Halo Spin-Out SPV Inc. The company will not receive proceeds from these resales.
As of December 19, 2025, SRx had 69,555,603 common shares outstanding, and the registered resale shares represent about 7% of its fully diluted share count. The prospectus highlights substantial financing activity, including secured convertible notes, preferred stock with attached warrants, and a $1.0 billion equity line of credit, alongside a going concern warning and a stated need for additional capital. SRx’s operating focus centers on its Halo pet health and wellness brand, while its Canadian affiliate is in CCAA restructuring. The company has also agreed to a proposed all-stock acquisition of EMJ Crypto Technologies Inc. and related assets valued at approximately $55 million, subject to shareholder and regulatory approvals.
SRx Health Solutions, Inc. has filed an amended registration statement covering the resale of up to 2,506,893,959 shares of common stock by Keystone Capital Partners under an equity line of credit structure. These Keystone Purchase Shares are tied to a Common Share Purchase Agreement that, as amended, allows SRx to sell up to $1.0 billion of stock to Keystone, while this prospectus registers Keystone’s potential resales, from which SRx will not receive proceeds.
The registered shares represent approximately 91.9% of SRx’s fully diluted common stock as of the prospectus date, compared with 27,723,906 shares outstanding and 218,636,279 shares on a fully diluted basis. The company warns that full resale could significantly depress the trading price and make raising additional equity more difficult. SRx carries a going concern warning, is highly dependent on external financing, and has recently undertaken multiple financings, a merger with SRx Canada, Canadian restructuring proceedings, PIPE transactions, and a large increase in authorized shares to 5,000,000,000.
SRx Health Solutions, Inc. filed a Form S-1 to register the resale of up to 101,865,909 shares of common stock by selling stockholders. This is a secondary offering; the company will not receive proceeds from any sales under this prospectus. The registered shares comprise multiple sources, including shares issuable upon conversion of Series A Preferred Stock and upon exercise of warrants issued in the July and October 2025 PIPE financings, exchangeable shares from SRx Canada, a prior private placement, service provider issuances, and shares issued in a share exchange.
The filing notes that these shares represent a considerable percentage of the public float and that resales could pressure the market price. Shares of common stock outstanding were 24,992,539 as of November 5, 2025; this is a baseline figure, not the amount being offered. SRXH is listed on NYSE American. The company states it will not receive any proceeds from selling stockholders’ resales and highlights risks related to future capital needs, potential dilution from future financings, and other operational and market factors.
SRx Health Solutions, Inc. filed an S-1 registering up to 82,000,000 shares of common stock for resale by Keystone Capital Partners. These shares are outstanding or issuable under a Common Share Purchase Agreement, and the Selling Stockholder will receive all proceeds from any resales. We are not selling securities in this prospectus and will not receive proceeds from the Selling Stockholder’s sales.
The Company may, at its discretion, sell shares to Keystone under an equity line, with potential aggregate gross proceeds of up to $1.0 billion subject to agreement terms and market conditions. The 82,000,000 shares offered for resale represent approximately 40.64% of total fully diluted outstanding shares as of this prospectus. Shares outstanding were 24,992,539 as of October 31, 2025. Our common stock trades on NYSE American under “SRXH”; the October 31, 2025 closing price was $0.3000 per share.
The filing notes NYSE American’s 19.99% Exchange Cap and a 4.99% beneficial ownership limit applicable to the Selling Stockholder. The Company will pay certain registration expenses; sale methods are as described under Plan of Distribution.